Bortezomib & Plasma cell myeloma

14.5%

of users reported Plasma cell myeloma

91.5%

also reported Severe reaction

60.3%

are men

Severe reaction

91.5%

Death

6.5%

Hospitalization

1.6%

Life-threatening condition

0.4%

Bortezomib: general information

0 - 9 years

0.5%

10 - 19 years

1.1%

20 - 29 years

0.4%

30 - 39 years

2.5%

40 - 49 years

6.6%

50 - 59 years

19.5%

60 - 69 years

32.9%

70 - 79 years

31.2%

80 - 89 years

5.3%